Means Investment CO. Inc. Sells 22,379 Shares of Pfizer Inc. $PFE

Key Points

• Means Investment CO. Inc. has reduced its holdings in Pfizer Inc. by 60.4%, selling 22,379 shares and leaving it with 14,687 shares worth approximately $356,000.
• Pfizer reported a quarterly earnings beat with earnings per share of $0.78, surpassing analysts' estimates of $0.58, and a revenue of $14.65 billion.
• The company declared a quarterly dividend of $0.43 per share, with a yield of 6.9%, set to be paid on December 1st to investors of record on November 7th.

Means Investment CO. Inc. lessened its position in Pfizer Inc. (NYSE:PFE - Free Report) by 60.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 14,687 shares of the biopharmaceutical company's stock after selling 22,379 shares during the period. Means Investment CO. Inc.'s holdings in Pfizer were worth $356,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in Pfizer by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock worth $13,257,004,000 after acquiring an additional 4,629,976 shares during the last quarter. Northern Trust Corp grew its holdings in Pfizer by 6.8% in the 1st quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company's stock worth $1,579,340,000 after acquiring an additional 3,943,397 shares during the last quarter. Amundi grew its holdings in Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock worth $1,265,277,000 after acquiring an additional 15,758,846 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Pfizer by 2.8% during the 1st quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company's stock valued at $767,709,000 after purchasing an additional 838,198 shares in the last quarter. Finally, Deutsche Bank AG boosted its stake in shares of Pfizer by 7.0% during the 1st quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company's stock valued at $715,581,000 after purchasing an additional 1,846,436 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Trading Down 1.7%

Shares of NYSE PFE opened at $24.81 on Friday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $29.82. The stock has a market cap of $141.03 billion, a P/E ratio of 13.19, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55. The firm has a 50-day moving average of $24.86 and a 200 day moving average of $24.13. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same period last year, the company posted $0.60 EPS. Pfizer's revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer's dividend payout ratio (DPR) is 91.49%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Bank of America lifted their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a research note on Friday, October 3rd. Wall Street Zen lowered shares of Pfizer from a "buy" rating to a "hold" rating in a research note on Sunday, September 28th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Pfizer in a research note on Wednesday. Morgan Stanley cut their target price on shares of Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a research note on Friday. Finally, UBS Group reaffirmed a "neutral" rating and set a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $28.35.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.